BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade)

Stock Information for Inozyme Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inozyme Pharma Inc.

BioMarin Announces Completion of Acquisition of Inozyme
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, SVT, HLGN on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq - INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq - PTIX)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVDX, TASK, INZY on Behalf of Shareholders
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TXNM, SVT, INZY, PTIX on Behalf of Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.